The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Surufatinib combined with TAS-102 as a late-line therapy in patients with metastatic pancreatic cancer (mPDAC): Updated results of a single-arm, phase II trial.
 
Dong-Sheng Zhang
No Relationships to Disclose
 
Yun-Xin Lu
No Relationships to Disclose
 
Fu-Rong Liu
No Relationships to Disclose
 
Bing Bai
No Relationships to Disclose
 
Yang Zhang
No Relationships to Disclose
 
Zhiqiang Wang
No Relationships to Disclose
 
Yu Liu
No Relationships to Disclose
 
Jian-Wen Chen
No Relationships to Disclose
 
Yu-Hong Li
No Relationships to Disclose
 
Feng-Hua Wang
No Relationships to Disclose
 
Gui Fang Guo
No Relationships to Disclose
 
Feng Wang
No Relationships to Disclose
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; CPPC; Hengrui Pharm; Hutchison MediPharma; Innovent Biologics; Junshi Pharmaceuticals; Keymed Biosience; Merck Serono; MSD; QiLu Pharmaceutical; Roche